Drugs / CTNX-4975
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02550756 | Feb → Nov 2014 | Morton neuroma | Centrexion Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTNX-4975 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02550756 ↗ |
| Known as | CNTX-4975 | “CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300.” NCT02550756 ↗ |